Theravance Biopharma Unveils 2025 Financial Performance and Strategic Direction Theravance Biopharma reports strong financial results for 2025, driven by record sales of YUPELRI® and outlines plans for future growth. A significant restructuring is also underway.

Theravance Biopharma Unveils 2025 Financial Performance and Strategic Direction #Ireland #Dublin #Theravance_Biopharma #YUPELRI #CYPRESS_Study

Theravance Biopharma Faces Challenges as CYPRESS Study Falls Short of Goals Theravance Biopharma announced disappointing results from the Phase 3 CYPRESS study, leading to a strategic review and significant cost-cutting measures.

Theravance Biopharma Faces Challenges as CYPRESS Study Falls Short of Goals #None #Theravance_Biopharma #YUPELRI #CYPRESS_Study

Theravance Biopharma to Engage in Investor Conferences This December Theravance Biopharma will participate in significant investor conferences in December 2025, showcasing industry leadership and innovations.

Theravance Biopharma to Engage in Investor Conferences This December #None #YUPELRI #Theravance #TBPH

Theravance Biopharma Releases Impressive Q3 2025 Financial Results and Future Plans Theravance Biopharma announces strong Q3 2025 financial results, highlighting record sales of YUPELRI and plans for upcoming pivotal trials.

Theravance Biopharma Releases Impressive Q3 2025 Financial Results and Future Plans #None #Theravance_Biopharma #YUPELRI #Ampreloxetine

Theravance Biopharma Unveils Significant YUPELRI Outcomes at 2025 CHEST Annual Meeting Theravance Biopharma is set to present compelling findings on YUPELRI® at the 2025 CHEST Annual Meeting, showcasing improved patient outcomes in COPD.

Theravance Biopharma Unveils Significant YUPELRI Outcomes at 2025 CHEST Annual Meeting #United_States #Chicago #Theravance_Biopharma #YUPELRI #COPD

Theravance Biopharma Explores Investment Opportunities at Global Conference Theravance Biopharma, Inc. will present at H.C. Wainwright's annual investment conference, discussing innovations and growth strategies.

Theravance Biopharma Explores Investment Opportunities at Global Conference #United_States #New_York_City #Theravance_Biopharma #YUPELRI #Ampreloxetine

Theravance Biopharma's Second Quarter 2025 Financial Results: A Corporate Update Theravance Biopharma has reported its financial results for the second quarter of 2025, highlighting growth and milestones achieved.

Theravance Biopharma's Second Quarter 2025 Financial Results: A Corporate Update #United_States #Dublin #Theravance_Biopharma #YUPELRI #Ampreloxetine

Theravance Biopharma Prepares for Engagement at the BTIG Virtual Biotechnology Conference Theravance Biopharma is set to engage in a fireside chat at the BTIG Virtual Biotechnology Conference on July 30, 2025, showcasing its innovative therapies.

Theravance Biopharma Prepares for Engagement at the BTIG Virtual Biotechnology Conference #Ireland #Dublin #Theravance_Biopharma #YUPELRI #BTIG_Conference

Theravance Biopharma's YUPELRI Approved in China, Marks a Milestone in COPD Treatment Theravance Biopharma celebrates the approval of YUPELRI by China's NMPA, ushering in a new era for COPD management with significant financial implications.

Theravance Biopharma's YUPELRI Approved in China, Marks a Milestone in COPD Treatment #China #Dublin #Theravance_Biopharma #YUPELRI #Viatris

Theravance Biopharma Engages Investors at Upcoming BioConnect Conference in NYC Theravance Biopharma, Inc. will showcase its innovative therapies during the BioConnect Investor Conference, initiating discussions for future growth.

Theravance Biopharma Engages Investors at Upcoming BioConnect Conference in NYC #United_States #New_York_City #Theravance_Biopharma #YUPELRI #Ampreloxetine

Theravance Biopharma Reports Positive Q1 2025 Financial Performance and Strategic Updates Theravance Biopharma has released its financial results for Q1 2025 alongside significant operational updates on key products, including YUPELRI and ampreloxetine.

Theravance Biopharma Reports Positive Q1 2025 Financial Performance and Strategic Updates #USA #Dublin #Theravance_Biopharma #YUPELRI #Ampreloxetine

Theravance Biopharma Reports Exceptional Financial Growth for Q4 and Full Year 2024 Theravance Biopharma achieved record financial results for Q4 and FY 2024, with significant sales growth driven by YUPELRI® and TRELEGY milestones.

Theravance Biopharma Reports Exceptional Financial Growth for Q4 and Full Year 2024 #Ireland #Dublin #Theravance_Biopharma #YUPELRI #TRELEGY

Theravance Biopharma to Showcase Innovations at Oppenheimer Conference in February 2025 Theravance Biopharma is set to present at the upcoming Oppenheimer Healthcare Life Sciences Conference, highlighting its innovative therapies.

Theravance Biopharma to Showcase Innovations at Oppenheimer Conference in February 2025 #Ireland #Dublin #Theravance_Biopharma #YUPELRI #Ampreloxetine

Theravance Biopharma to Host Investor Meetings at Upcoming Healthcare Conference in San Francisco Theravance Biopharma has announced its participation in the J.P. Morgan Healthcare Conference, offering opportunities for private investor meetings during this key event.

Theravance Biopharma to Host Investor Meetings at Upcoming Healthcare Conference in San Francisco #United_States #San_Francisco #J.P._Morgan #Theravance_Biopharma #YUPELRI